期刊文献+

miR-146a和LIN52在甲状腺癌中表达水平及与化疗敏感性和预后的关系 被引量:9

Expression of miR-146a and LIN52 in thyroid carcinoma and its relationship with chemotherapeutic sensitivity and prognosis of patients
下载PDF
导出
摘要 目的探讨miR-146a和LIN52在甲状腺癌中表达水平及其与化疗敏感性和预后的关系。方法选取确诊的甲状腺癌患者98例,收集患者癌组织与癌旁组织标本,采用逆转录实时荧光定量法和免疫组化法测定miR-146a、LIN52的表达水平,分析其与临床病理特征、化疗敏感性及预后的关系。结果癌组织中miR-146a mRNA表达量低于癌旁组织,LIN52 mRNA表达量高于癌旁组织(t=36.182、44.023,P<0.01);癌组织miR-146a阳性率低于癌旁组织,LIN52阳性率高于癌旁组织(χ~2=111.942、100.178,P<0.01);miR-146a、LIN52 mRNA表达与年龄相关性不明显(χ~2=0.248、0.284,P>0.05),与病理学分级、TMN分期、浸润深度、淋巴血管间隙浸润、淋巴结转移及化疗敏感性相关性明显,且病理学分期越高、TMN分期越高、浸润深度越深、淋巴血管间隙浸润、有淋巴结转移、化疗敏感性低患者miR-146a阳性表达率较低,LIN52阳性表达率较高(χ~2=19.934、10.292、25.514、7.728、8.738、27.774、20.327、10.458、32.932、6.756、13.162、18.506,P<0.05);miR-146a阳组3年生存率及生存期均明显高于miR-146a阴组,LIN52阳组3年生存率及生存期均明显低于LIN52阴组(χ~2=64.542、27.993、29.142、22.982,P<0.01)。结论 miR-146a在甲状腺癌组织的表达量低于癌旁组织,而LIN52表达量高于癌旁组织;miR-146a与化疗敏感性正相关,而LIN52与化疗敏感性负相关,miR-146a表达阳性、LIN52表达阴性的患者能获得较好的预后。 Objective To investigate the expression of miR-146 a and LIN52 in thyroid carcinoma and its relationship with chemotherapeutic sensitivity and prognosis of patients.Methods A total of 98 patients with thyroid carcinoma who were definitely diagnosed in our hospital were enrolled in the study.The specimens of cancer tissue and paracancerous tissue were collected.The expression levels of miR-146 a and LIN52 were detected by reverse transcriptase by real-time fluorescence quantitative PCR and immunohistochemical method.The relationship between the expression levels of miR-146 a,LIN52 and chemosensitivity,clinical features,patient’s prognosis was analyzed.Results The expression levels of miR-146 a mRNA in cancer tissues were significantly lower than those in cancer adjacent tissues,however,the expression levels of LIN52 mRNA in cancer tissues were significantly higher than those in cancer adjacent tissues(P<0.01).The positive rate of miR-146 a in cancer tissues was significantly lower than that in cancer adjacent tissues,but the positive rate of LIN52 was significantly higher than that in cancer adjacent tissues(P<0.01).The expression levels of MiR-146 a and LIN52 mRNA were not obviously correlated with age(P>0.05),however,which were closely correlated with pathological grade,TMN stage,invasion depth,lymph vascular space invasion,lymph node metastasis and chemotherapy sensitivity,moreover,the higher pathological staging,TMN staging,infiltration depth,lymph vascular space invasion,lymph node metastasis and lower sensitivity to chemotherapy,the lower the miR-146 a positive expression rates and the higher the LIN52 positive expression rates(P<0.05).Moreover the 3-year survival rate and survival duration in miR-146 a positive expression group were significantly higher than those in miR-146 a negative expression group,and the 3-year survival rate and survival duration in LIN52 positive expression group were significantly lower than those in LIN52 negative expression group(P<0.01).Conclusion The expression levels of miR-146 a in thyroid carcinoma tissues are lower than those in paracancerous tissues,however,the expression levels of LIN52 are higher than those in paracancerous tissues.MiR-146 a expression is positively correlated with chemosensitivity,but LIN52 expression is negatively correlated with chemosensitivity.The thyroid cancer patients with positive expression of miR-146 a or negative expression of LIN52 can achieve better prognosis.
作者 夏少华 胥然 李树华 袁婧 XIA Shaohua;XU Ran;LI Shuhua(Department of ENT,Central Hospital of Mianyang City,Sichuan,Mianyang 621000,China)
出处 《河北医药》 CAS 2019年第4期498-502,共5页 Hebei Medical Journal
基金 四川省卫生厅科研课题项目(编号:160063)
关键词 MIR-146A LIN52 甲状腺癌 化疗敏感性 miR-146a LIN52 thyroid cancer chemosensitivity
  • 相关文献

参考文献7

二级参考文献74

  • 1俞明细,王有成,强金伟.甲状腺肿瘤性病变的CT诊断[J].中国医学影像学杂志,2004,12(6):465-467. 被引量:16
  • 2俞炎平,郑家平,孙文勇,邵国良,庞伟强.甲状腺腺瘤143例CT影像分析[J].中国肿瘤,2005,14(6):395-397. 被引量:24
  • 3张建伟,刘海泉,杨建伟,贾丙鑫,李辛.CT对甲状腺肿瘤的鉴别诊断价值[J].实用放射学杂志,2005,21(11):1154-1156. 被引量:21
  • 4Colquhoun A, Arnold M, Ferlay J, et al. Global palterns of cardia and non-cardia gastric cancer incidence in 2012 [ J 1- Gut, 2015, 64 ( 12 ) : 1881-1888. DOI: 10.1136/gntjnl-2014-308915.
  • 5Sempere LF. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer [ J 1. Expert Rev Mol Diagn, 2011, 11 ( 8 ) : 813-827. DOh 10.1586/erm.11.69.
  • 6Imam JS, BuddavarapuK, Lee-ChangJS, etal. MicroRNA-185 suppresses tumor growth and progression by targeting the Sixl oncogene in human cancers [ J ]. Oncogene, 2010, 29 ( 35 ) : 4971- 4979. DOh 10.1038/onc.2010.233.
  • 7Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis ( review ) [ J ]. Oncol Lett, 2015, 9 ( 4 ) : 1502-1508. DOh 10.3892/ol.2015.2959.
  • 8Yao Q, Cao Z, Tu C, et al. MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2 [ J ]. Cancer Lett, 2013, 335 ( 1 ) : 219-224. DOI: 10.1016/j.canlet.2013.02.031.
  • 9Hou Z, Xie L, Yu L, et al. MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis [ J 1. Med Oncol, 2012, 29( 2 ) : 886-892. DOh 10.1007/s12032-011-9862-7.
  • 10Kogo R, Mimori K, Tanaka F, et al. Clinical significance of miR- 146a in gastric cancer cases [ J 1. Clin Cancer Res, 2011, 17 ( 13 ) : 4277-4284. DOI : 10.1158/1078-0432.CCR-10-2866.

共引文献109

同被引文献72

引证文献9

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部